At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XOMA XOMA Corp
Trading 11-08 15:49:58 EST
30.36
+0.16
+0.53%
High30.85Low30.36Vol17.72K
Open30.67D1 Closing30.20Amplitude1.62%
Mkt Cap355.35MTradable Cap243.76MTotal Shares11.70M
T/O543.00KT/O Rate0.22%Tradable Shares8.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
XOMA Royalty Corp : Leerink Partners Raises Target Price to $55 From $49
THOMSON REUTERS  ·  11-08 19:09
XOMA Royalty Corp : Leerink Partners Raises Target Price to $55 From $49
XOMA Royalty’s Third Quarter 2024 Financial Insights
TIPRANKS  ·  11-08 13:55
XOMA Royalty’s Third Quarter 2024 Financial Insights
XOMA Royalty Corp reports results for the quarter ended in September 30 - Earnings Summary
Reuters  ·  11-07 22:39
XOMA Royalty Corp reports results for the quarter ended in September 30 - Earnings Summary
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
Zacks  ·  11-07 22:00
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
XOMA Royalty: Q3 Earnings Snapshot
Associated Press Finance  ·  11-07 20:52
XOMA Royalty: Q3 Earnings Snapshot
XOMA Q3 2024 GAAP EPS $(1.59) Misses $(0.44) Estimate, Sales $9.197M Beat $6.493M Estimate
Benzinga  ·  11-07 20:45
XOMA Q3 2024 GAAP EPS $(1.59) Misses $(0.44) Estimate, Sales $9.197M Beat $6.493M Estimate
XOMA Royalty Qtrly Share Loss $1.59
THOMSON REUTERS  ·  11-07 20:30
XOMA Royalty Qtrly Share Loss $1.59
XOMA Royalty Qtrly Total Income and Revenues $7.2 Mln
THOMSON REUTERS  ·  11-07 20:30
XOMA Royalty Qtrly Total Income and Revenues $7.2 Mln
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
THOMSON REUTERS  ·  11-07 20:30
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Press Release: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Dow Jones  ·  11-07 20:30
Press Release: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Royalty Corp expected to post a loss of 44 cents a share - Earnings Preview
Reuters  ·  11-01
XOMA Royalty Corp expected to post a loss of 44 cents a share - Earnings Preview
XOMA Royalty Down Nearly 11%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk
Dow Jones  ·  10-30
XOMA Royalty Down Nearly 11%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk
XOMA Price Target Maintained With a $117.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-23
XOMA Price Target Maintained With a $117.00/Share by HC Wainwright & Co.
XOMA Royalty Acquires Royalty Interest in Twist Bioscience's Biopharma Programs
MT Newswires Live  ·  10-22
XOMA Royalty Acquires Royalty Interest in Twist Bioscience's Biopharma Programs
XOMA Royalty: on Oct 21 XOMA Entered Royalty Purchase Agreement With Twist Bioscience
THOMSON REUTERS  ·  10-22
XOMA Royalty: on Oct 21 XOMA Entered Royalty Purchase Agreement With Twist Bioscience
Xoma enters $15M royalty monetization arrangement with Twist Bioscience
TIPRANKS  ·  10-22
Xoma enters $15M royalty monetization arrangement with Twist Bioscience
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
GlobeNewswire  ·  10-22
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
Business Wire  ·  10-22
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year
Simply Wall St.  ·  10-21
Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
seekingalpha  ·  10-15
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Introduction

Company Name.
XOMA Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Issue price:
--